Publications by authors named "Roberta Fantozzi"

Article Synopsis
  • The study investigates the effects of discontinuing dimethyl fumarate (DMF) during early pregnancy in women with multiple sclerosis (MS), analyzing 137 pregnancies from Italian MS Centers.
  • Results show that disease activity typically decreases during pregnancy but increases postpartum; higher relapse rates before conception correlate with faster relapses after giving birth.
  • Importantly, DMF exposure during early pregnancy did not negatively affect fetal outcomes, suggesting it is safe for the pregnancy context.
View Article and Find Full Text PDF

Proinflammatory cytokines are implicated in promoting neurodegeneration in multiple sclerosis (MS) by affecting excitatory and inhibitory transmission at central synapses. Conversely, the synaptic effects of anti-inflammatory molecules remain underexplored, despite their potential neuroprotective properties and their presence in the cerebrospinal fluid (CSF) of patients. In a study involving 184 newly diagnosed relapsing-remitting (RR)-MS patients, we investigated whether CSF levels of the anti-inflammatory interleukin (IL)-10 were linked to disease severity and neurodegeneration measures.

View Article and Find Full Text PDF
Article Synopsis
  • SPMS progresses from a relapsing-remitting phase and is marked by increasing disability, but lacks a reliable tool to track this transition; T cells from RRMS patients worsen neuron function, indicating synaptotoxic effects in SPMS.
  • The study collected data from healthy controls and SPMS patients, analyzing the effects of siponimod on T cell interactions in brain slices and using animal models to pinpoint how siponimod helps.
  • Results showed that T cells from SPMS patients increased excitatory signals in neurons compared to healthy controls, while siponimod reversed this toxicity, suggesting it could be a vital treatment strategy for managing SPMS.
View Article and Find Full Text PDF

Background: in the early stages of Multiple Sclerosis (MS), initiating high-efficacy disease-modifying therapy (HE DMTs) may represent an optimal strategy for delaying neurological damage and long-term disease progression, especially in highly active MS patients (HAMS). Natalizumab (NAT) and Ocrelizumab (OCR) are recognized as HE DMTs with significant anti-inflammatory effects. This study investigates NEDA-3 achievement in treatment-naïve HAMS patients receiving NAT or OCR over three years.

View Article and Find Full Text PDF

Background: The management of Multiple Sclerosis (MS) has undergone transformative evolution with the introduction of high-efficacy disease-modifying therapies (DMTs), specifically anti-CD20 monoclonal antibodies, such as ocrelizumab (OCR) and ofatumumab (OFA).

Materials And Methods: This is an independent retrospective cohort study in Relapsing MS (RMS) patients followed at eight Italian MS centers who initiated treatment with OCR or OFA in the participating centers and with at least 12 months on therapy. A generalized linear regression model inverse probability of treatment weight (IPTW) PS-adjusted was performed to evaluate the relationship between annualized relapse rate (ARR) and treatment groups.

View Article and Find Full Text PDF
Article Synopsis
  • * A study involving 204 patients who completed two years of cladribine treatment found that 75.4% did not start new treatments in the year following therapy, and there was a significant reduction in relapse rates after treatment.
  • * The results suggest that cladribine is effective in lowering relapse rates and has a favorable safety profile, with lymphopenia being the main side effect; however, further larger studies are needed to confirm its long
View Article and Find Full Text PDF
Article Synopsis
  • Maternal COVID-19 is linked to worse outcomes for mothers, but its effects on pregnant women with multiple sclerosis (MS) had not been thoroughly examined prior to this study.
  • This multicenter study focused on pregnant women with MS who contracted COVID-19, assessing their maternal and fetal health outcomes compared to a control group.
  • Findings revealed that while COVID-19 increased the risk of maternal complications, it did not significantly affect rates of spontaneous abortion or fetal malformations.
View Article and Find Full Text PDF

Despite its widespread use in clinical practice, the effectiveness of natalizumab extended interval dosing (EID) adopted from treatment start across different treatment intervals and individual modifiers (body mass index - BMI) is still under-investigated. Here, seven-hundred and forty-five multiple sclerosis (MS) patients, exposed to natalizumab for 3.30 ​± ​1.

View Article and Find Full Text PDF

Objective: Multiple sclerosis (MS) is a complex disorder in which environmental and genetic factors interact modifying disease risk and course. This multicentre, case-control study involving 18 Italian MS Centres investigated MS course by ethnicity and native-country economic status in foreign-born patients living in Italy.

Methods: We identified 457 MS patients who migrated to Italy and 893 age- and sex-matched native-born Italian patients.

View Article and Find Full Text PDF
Article Synopsis
  • COVID-19 vaccines, specifically mRNA types, have been recommended for people with multiple sclerosis (pwMS), and many have received a third booster dose for better immunity.
  • A study involving 1265 pwMS investigated the short-term risk of disease reactivation after this booster shot, assessing relapse rates before and after vaccination.
  • The results showed no significant increase in relapse rates post-booster (2.1%) compared to the rates before vaccination (1.9%), indicating that the third booster dose is likely safe for pwMS.
View Article and Find Full Text PDF

Background: Ofatumumab (OFA) is a fully human anti-CD20 monoclonal antibody administered with a 20 mg subcutaneous monthly dosing regimen.

Methods: Inclusion criteria were patients: 1) aged 18-55; 2) with a confirmed diagnosis of relapsing Multiple Sclerosis (RMS), per the revised 2010 McDonald criteria; 2) who started OFA according to Italian Medicines Agency prescription rules and within 12 months from the RMS diagnosis; 3) naïve to any disease-modifying therapy. The primary outcome was to offer an overview of cellular subsets of RMS naïve patients (time 0) and then after 4 weeks (time 1) and 12 weeks (time 2) on therapy with OFA in a real-world setting.

View Article and Find Full Text PDF

Background: Little is known about COVID-19 course and outcomes after a third booster dose of mRNA vaccine against SARS-CoV-2 (mRNA-Vax) in patients with multiple sclerosis (pwMS) treated with ocrelizumab (OCR) and fingolimod (FNG), which showed a weakened immune response to mRNA-vax.

Objectives: The aim of this study was to evaluate COVID-19 course and outcomes in pwMS on OCR and FNG after receiving the third dose of mRNA-Vax and to compare it with pwMS on natalizumab (NTZ).

Methods: Inclusion criteria: >18 years of age, being treated with OCR/FNG/NTZ since the first mRNA-Vax dose; COVID-19 after a third booster dose of mRNA-Vax; no steroids use.

View Article and Find Full Text PDF

Recent cross-sectional investigations suggest a relationship between frailty, as measured by Frailty Index (FI), and multiple sclerosis (MS). However, if and how frailty is associated with relapse activity in MS is still unknown. To explore this issue, a one-year follow-up study involving 471 patients was conducted.

View Article and Find Full Text PDF

Background: Clinicians are increasingly recognizing the importance of shared decision-making in complex treatment choices, highlighting the importance of the patient's rationale and motivation for switching therapies. This study aimed to evaluate the association between different modalities of changing multiple sclerosis (MS) treatments, cognitive profile and attitude and preferences of patients concerning treatment choice.

Methods: This multicenter cross-sectional study was conducted at 28 Italian MS centers in the period between June 2016 and June 2017.

View Article and Find Full Text PDF
Article Synopsis
  • The study aims to evaluate the risk of multiple sclerosis (MS) reactivation during and after pregnancy in women treated with natalizumab (NTZ), comparing those who continued treatment (LONG_EXP) with those who interrupted it before or shortly after conception (NO_EXP, SHORT_EXP).
  • Results showed that women who continued NTZ during pregnancy had a significantly lower annualized relapse rate and fewer gadolinium-enhancing lesions than those who interrupted treatment.
  • Newborns' health outcomes were similar across the groups, with no significant differences in weight, length, or head circumference, although there was a slight incidence of anemia in the LONG_EXP group.
View Article and Find Full Text PDF

Background: Elevated levels of specific proinflammatory molecules in the cerebrospinal fluid (CSF) have been associated with disability progression, enhanced neurodegeneration and higher incidence of mood disorders in people with multiple sclerosis (MS). Studies in animal models of MS suggest that preventive exercise may play an immunomodulatory activity, with beneficial effects on both motor deficits and behavioral alterations. Here we explored the impact of lifestyle physical activity on clinical presentation and associated central inflammation in a large group of newly diagnosed patients with MS.

View Article and Find Full Text PDF

This study aimed to assess the usability of a specific EU-available application device for Sativex (US adopted name: nabiximols) cannabinoid-based oromucosal spray in patients with multiple sclerosis (MS) and spasticity-related upper limb and hand impairment in routine daily practice. MS patients with upper limb and hand impairment evaluated the usability of the device using an 18-item questionnaire. 60 patients were included.

View Article and Find Full Text PDF

Introduction: Cladribine administration has been approved for the treatment of relapsing-remitting multiple sclerosis (MS) in 2017; thus, data on cladribine in a real-world setting are still emerging.

Methods: We report on cladribine effectiveness, safety profile, and treatment response predictors in 243 patients with MS followed at eight tertiary MS centers. Study outcomes were: (1) No Evidence of Disease Activity-3 (NEDA-3) status and its components (absence of clinical relapses, MRI activity, and sustained disability worsening); (2) development of grade III/IV lymphopenia.

View Article and Find Full Text PDF

Background And Objectives: To investigate the longitudinal dynamic of lymphocyte subsets during treatment with ocrelizumab (OCR) in patients with multiple sclerosis (PwMS).

Methods: A multicenter retrospective study was conducted in 161 PwMS starting treatment with OCR grouped in naive (naive, n = 40), switching from fingolimod (FTY, n = 52), and switching from other immunomodulating drugs (other, n = 69). Mean lymphocyte subset (total, CD3, CD4, CD8, CD20, and natural killer) counts were analyzed at baseline, 6 months, and 12 months.

View Article and Find Full Text PDF

COVID-19 pandemic represented a challenge in the management of treatments for Multiple Sclerosis (MS), such as Natalizumab (NTZ). NTZ interferes with the homing of lymphocytes into the central nervous system, reducing immune surveillance against opportunistic infection. Although NTZ efficacy starts to decline 8 weeks after the last infusion, increasing the risk of disease reactivation, evidence is lacking on the safety of reinfusion during active SARS-CoV-2 infection.

View Article and Find Full Text PDF

Age at onset is the main risk factor for disease progression in patients with relapsing-remitting multiple sclerosis (RR-MS). In this cross-sectional study, we explored whether older age is associated with specific disease features involved in the progression independent of relapse activity (PIRA). In 266 patients with RR-MS, the associations between age at onset, clinical characteristics, cerebrospinal fluid (CSF) levels of lactate, and that of several inflammatory molecules were analyzed.

View Article and Find Full Text PDF

Excessive extracellular concentrations of L-glutamate (L-Glu) can be neurotoxic and contribute to neurodegenerative processes in multiple sclerosis (MS). The association between cerebrospinal fluid (CSF) L-Glu levels, clinical features, and inflammatory biomarkers in patients with MS remains unclear. In 179 MS patients (relapsing remitting, RR, N = 157; secondary progressive/primary progressive, SP/PP, N = 22), CSF levels of L-Glu at diagnosis were determined and compared with those obtained in a group of 40 patients with non-inflammatory/non-degenerative disorders.

View Article and Find Full Text PDF

Recent studies estimated an incidence of 4-25% of disease rebound after withdrawal of fingolimod (FTY) for any reason, but specific data on disease reactivation after FTY withdrawal due to pregnancy are limited. The aim of the study was to evaluate the frequency and predictors of disease reactivation in patients who stopped FTY for pregnancy. A multicentre retrospective cohort study was conducted in four Italian MS centres in 2013-2019.

View Article and Find Full Text PDF

Since the recent approval of vaccines against COVID-19, efficacy concerns emerged for MS patients treated with immunosuppressive drugs. We report our experience in four patients, under cladribine (two) or under ocrelizumab (two) treatment, all with low lymphocyte count, three of them vaccinated after 3 months from the last dose with good immune response, one (under ocrelizumab) after 2 months, without developing an appropriate title of antibodies. This experience suggests that the discriminant for the response to the vaccine is not the lymphocyte count but the timing of the vaccination.

View Article and Find Full Text PDF